news
Alzheimer's research pivots to tau, blood-brain barrier
At the Alzheimer’s Association International Conference (AAIC), researchers highlighted new strategies targeting tau proteins and improving drug delivery across the blood-brain barrier. The focus moves beyond solely amyloid plaques, hinting at more effective interventions for cognitive decline.
At the Alzheimer’s Association International Conference (AAIC), researchers highlighted new strategies targeting tau proteins and improving drug delivery across the blood-brain barrier. The focus moves beyond solely amyloid plaques, hinting at more effective interventions for cognitive decline.
The architecture take
The pivot from amyloid-fixation to tau-targeting and blood-brain barrier innovation is big. For years, Alzheimer's drug development was stuck on amyloid, despite repeated failures to actually stop cognitive decline. Now, they're looking at tau tangles—the actual wreckage inside neurons—and figuring out how to get therapies past the brain's VIP velvet rope (the blood-brain barrier). This isn't just a science wonk thing; it means the meds hitting your system could actually get to where they need to go, making a difference in the disease's progression. It's a pragmatic shift: if the existing keys aren't opening the lock, you find a new lock or a better key. This reorientation toward more immediate mechanisms of neuronal damage and better delivery means a higher chance of a treatment that impacts how our cognition holds up as we age.